Mission Hospital One of Two Hospitals in Nation with Access to New Test
(Mission Viejo, Calif. – February 3, 2020) – Mission Hospital has announced that its Judi and Bill Leonard Institute for Cancer Prevention, Treatment and Wellness now has access to DetermaRx, formerly known as the Razar treatment stratification test. The test enables the identification of early stage lung cancer by identifying patients who may benefit from chemotherapy after surgery. Mission Hospital is one of two hospitals in the nation with early access to the test.
“For more than four decades, Mission Hospital has been committed to providing innovative and high-quality care for residents of South Orange County,” said Seth Teigen, chief executive of Mission Hospital. “Our early access partnership with DetermaRx allows us to enhance our comprehensive lung cancer treatment program and optimize post-surgical treatment decisions.”
Under the current standard of care, about 30-to-50 percent of stage I – IIA patients who have had surgery to remove lung tumors tend to experience a cancer recurrence and die within five years of surgery. Mission Hospital’s access to DetermaRx allows high-risk patients to receive chemotherapy immediately after surgery to help better overall health outcomes and survival rates.
Additionally, DetermaRx will provide Leonard Cancer Institute physicians with personalized lung cancer treatment management by identifying patients at an early stage, especially as all stages aren’t the same and each carry a varying risk of recurrence. Additionally, the test has the potential to detect patients carrying a high-risk for recurrence based on their genomic profile.
DetermaRx is made available by Oncocyte Corporation (NYSE American: OCX), a molecular diagnostic company with a mission to provide actionable answers at critical decision points across the lung cancer care continuum.
For additional information about the Judi and Bill Leonard Institute for Cancer Prevention, Treatment and Wellness at Mission Hospital, visit https://leonardcancerinstitute.com/
About Mission Hospital
Mission Hospital is a state-of-the-art, 523-bed acute care regional medical center in Mission Viejo, California. As one of the busiest designated adult and pediatric Level II Trauma Centers in the state of California, Mission Hospital provides a full range of reputable specialty health care services with highly skilled teams treating a multitude of complex conditions. Services include a full range of expertise in cardiovascular, neuroscience and spine, orthopedics, cancer care, women’s services, mental health and wellness, and a variety of other specialty services.
Mission Hospital in Laguna Beach (MHLB) provides South Orange County coastal communities with 24-hour emergency and intensive care as well as medical-surgical/telemetry services, orthopedics, general and GI surgery. CHOC Children’s at Mission Hospital is a 54-bed facility that is the area’s only dedicated pediatric hospital.
Fully accredited by The Joint Commission and designated as a Magnet hospital by the American Nurses Credentialing Center for nursing excellence, Mission Hospital is highly recognized for its high quality of care, evidenced through a multitude of healthcare quality benchmarks. Mission Hospital is part of Providence, a not-for-profit provider of integrated health care. Together, we work to improve the quality of life in the communities it serves in the tradition of the Sisters of Providence and the Sisters St. Joseph of Orange. For more information, visit www.mission4health.com.
DetermaRx is a molecular diagnostic test that enables the identification of early-stage lung cancer patients who may benefit from chemotherapy following surgery, allowing them to be treated when their cancer may be more responsive to adjuvant chemotherapy. The test utilizes a gene expression analysis of 14 specific genes from a patient’s tumor and a proprietary algorithm to stratify early stage NSCLC patients into one of two groups, one that may benefit from chemotherapy because of high risk of recurrence, and another that may avoid chemotherapy because of low risk of recurrence.
DetermaRx is extensively validated and published with independent, blinded global studies in over 1,500 patients and seven publications in prestigious journals including the Lancet and JAMA.